Recently, the National Natural Science Foundation of China (NSFC) announced the review results for the "Original Cancer Target Confirmation and Early Research on Original Drugs" program in 2024. The project jointly applied for by BioTroy Therapeutics and Fudan University has received funding from the NSFC's special project.
The " Original Cancer Target Confirmation and Early Research on Original Drugs" special project aims to strengthen basic research on original anticancer drugs and promote the development of innovative cancer drugs in China.
The Funding is provided to research teams that have identified original potential targets clearly related to cancer onset, progression, metastasis, resistance or prognosis, with no drugs targeting the same target having entered clinical studies domestically or internationally, and who have obtained new drug candidates, to complete preclinical studies of these candidates and obtain permission for clinical trials.
"Our country's original innovation technologies are continuously increasing," said Dr. Jie Xu, founder of BioTroy Therapeutics, at the "2024 CHDC · Conference", where he elaborated, "we can see that the state is strongly supporting the development of original target drugs. With time, more valuable and translatable projects will emerge from academia, ultimately being pushed towards clinical use, benefiting more cancer patients."
